YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer

This study has been terminated.
Sponsor:
Collaborator:
Astellas Pharma US, Inc.
Information provided by:
Astellas Pharma Inc
ClinicalTrials.gov Identifier:
NCT00050297
First received: December 3, 2002
Last updated: June 6, 2012
Last verified: June 2012
  Purpose

The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.


Condition Intervention Phase
Prostate Cancer
Drug: YM598
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Study Completion Date: February 2004
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00050297

Locations
Belgium
University Clinic AZ
Brussels, Belgium
University Clinic UCL St. Luc
Brussels, Belgium
Czech Republic
Private Urology Out-patient Ward
Jablonec nad Nisou, Czech Republic
Clinic of Urology, University Hospital
Králové, Czech Republic
Clinic of Urology, University Hospital
Olomouc, Czech Republic
Clinic of Urology, University Hospital
Prague, Czech Republic
France
Hôpital Bichat, service de Urology
Paris, France
Germany
Haingasse 22
Bad Homburg, Germany, 61348
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
Dresden, Germany
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
Marburg, Germany
Krummbogen 15
Marburg, Germany
Poland
Regional Hospital, Department of Urology
Bydgoszcz, Poland
MedSource Poland
Gdansk, Poland
Oncology Center, Department of Urinary Tract Cancer
Warszawa, Poland
Bielanski Hospital, Department of Urology
Warszawa, Poland
Medical University, Clinic of Urology
Wroclaw, Poland
Spain
Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
Corunna, Spain
Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
Madrid, Spain
Fundacion Hospital Alcorcón, Servicio Urología
Madrid, Spain
United Kingdom
Department of Urology, Bristol Royal Infirmary
Bristol, United Kingdom
Department of Urology, Gartnavel Hospital
Glasgow, United Kingdom
Department of Urology, Norfolk & Norwich Hospital
Norwich, United Kingdom
Department of Urology, Taunton & Somerset Hospital
Taunton, United Kingdom
Sponsors and Collaborators
Astellas Pharma Inc
Astellas Pharma US, Inc.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00050297     History of Changes
Other Study ID Numbers: 598-CL-004
Study First Received: December 3, 2002
Last Updated: June 6, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on September 18, 2014